Latest Video Updates

Upcoming Oncology Education Events

OncologyEducation Events Video Archives

Oncology Clinical News

Merck Gets FDA Okay For Keytruda As Liver Cancer Therapy


Read full article.

FDA Grants Lynparza Priority Review for Frontline Maintenance in Ovarian Cancer

(Curetoday.com) Nov 12, 2018 - The FDA has granted a priority review designation to a supplemental new drug application (sNDA) for Lynparza (olaparib) tablets for use as a maintenance therapy in patients with newly-diagnosed, BRCA-positive advanced ovarian cancer who achieved a complete or partial response to standard frontline platinum-based chemotherapy. The sNDA is based on data from the phase 3 SOLO-1 trial, in which the PARP inhibitor Lynparza significantly improved progression-free survival (PFS) as frontline maintenance for this patient population. With a median follow-up of 41 months, the median PFS by independent central review was not reached in the Lynparza arm (260 patients), versus 14.1 months in the placebo arm (131 patients). The investigator-assessed PFS in the Lynparza arm was not reached, compared to 13.8 months in the placebo arm.
Read full article.

Vitamin D and Fish Oils Are Ineffective for Preventing Cancer and Heart Disease


Read full article.

Powered by OBR Oncology